clinical trial · NCT05904626
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Intestinal MalabsorptionELGN-2112Placebo
brief summary
To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
started
Oct 28, 2025
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Apr 9, 2026
official title
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Basket Study to Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol